PharmaPoint: Ulcerative Colitis-Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis-Global Drug Forecast and Market Analysis to 2025


  • Products Id :- GDHC142PIDR
  • |
  • Pages: 345
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

PharmaPoint: Ulcerative Colitis-Global Drug Forecast and Market Analysis to 2025

Summary

Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon's ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain, with urgency for bowel movement. Other associated symptoms of UC include loss of appetite, weight loss, fatigue, and anaemia in cases of severe bleeding. The exact causes or triggers of the disease are yet to be identified; however, it is known that in people with UC, the body's immune system mistakes bacteria, food, and other materials in the intestine for foreign substances and attacks the colon tissues, leading to chronic inflammation of the colon linings. UC is a relapsing, remitting chronic disease that requires life long medical management and patients. Attributing to unknown aetiology of UC, all current pharmacopoeia provide immunosuppressive, symptomatic relief, as no curative disease therapy is available yet. Based on disease location and severity, patients receive different treatment alternatives either for induction or maintenance of remission.

Highlights

Key Questions Answered

The newly launched anti-integrin antibody Entyvio and Remicade biosimilars, will see an increase in patient shares for the treatment of severe UC. Will these newly marketed make a significant impact on the UC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

The most notable candidate in the current late-stage UC pipeline is new generation ozanimod hydrochloride and Xeljanz (tofacitinib), which are predicted to have a notable impact in the moderate to severe UC space over this forecast period. However, there are still considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the UC market?

We have seen a notable increase in the UC population in terms of diagnosed prevalent UC cases for mild to moderate and moderate to severe disease. How will epidemiological changes impact the growth of the future market?

Key Findings

The main driver for the UC market will be the launch of Celgene's first-in-class Sphingosine 1 Phosphate Receptor 1 (S1P1) modulator, ozanimod hydrochloride, in all 6MM. Launch of Pfizer's Xeljanz, Johnson and Johnson's Stelara (ustekinumab), Lipid Therapeutics' LT-02, and Roche's etrolizumab will also contribute to global UC market growth.

The major global barrier for the UC market will be the sales erosion of blockbuster biologic drugs for moderate to severe UC space due to launch and increasing use of anti-tumor necrosis factor (TNF) biosimilars over this forecast period.

In the future, the dynamics of the lucrative moderate to severe UC market will shift greatly from the historical strategy of developing biologic drugs, towards small molecule oral drugs.

The key market opportunities lie in addressing unmet needs through the development of oral agents with superior efficacy and safety profile, low cost, curative UC therapy as well as drugs that help minimise colorectal cancer risk.

Scope

Overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global UC therapeutics market from 2015-2025.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 10

1.1 List of Tables 16

1.2 List of Figures 23

2 Introduction 25

2.1 Catalyst 25

2.2 Related Reports 26

2.3 Upcoming Related Reports 26

3 Disease Overview 27

3.1 Etiology and Pathophysiology 27

3.1.1 Etiology 27

3.1.2 Pathophysiology 31

3.2 Classification or Staging Systems 33

3.3 Symptoms 36

3.4 Quality of Life 36

4 Epidemiology 38

4.1 Disease Background 38

4.2 Risk Factors and Comorbidities 39

4.3 Global Trends 40

4.3.1 Incidence 41

4.3.2 Prevalence 44

4.4 Forecast Methodology 47

4.4.1 Sources Used 47

4.4.2 Forecast Assumptions and Methods 58

4.4.3 Sources Not Used 76

4.5 Epidemiological Forecast for UC (2015-2025) 77

4.5.1 Diagnosed Incident Cases of UC 77

4.5.2 Diagnosed Prevalent Cases of UC 85

4.5.3 Undiagnosed Prevalent Cases of UC 96

4.5.4 Total Prevalent Cases of UC 103

4.5.5 Diagnosed Incident Cases of IC 109

4.5.6 Diagnosed Prevalent Cases of IC 111

4.6 Discussion 112

4.6.1 Epidemiological Forecast Insight 112

4.6.2 Limitations of the Analysis 113

4.6.3 Strengths of the Analysis 114

4.6.4 Strengths of the Analysis 115

5 Disease Management 116

5.1 Diagnosis and Treatment Overview 116

5.1.1 Diagnosis 116

5.1.2 Treatment Guidelines and Leading Prescribed Drugs 121

5.1.3 Clinical Practice 123

5.2 US 129

5.3 5EU 131

5.4 Japan 135

6 Competitive Assessment 138

6.1 Overview 138

6.2 Product Profiles-Ulcerative Colitis 140

6.2.1 5-ASAs 140

6.2.2 Steroids 145

6.2.3 Thiopurines 150

6.2.4 Other Immunomodulators 154

6.2.5 Anti-TNF? drugs (Remicade, Humira, Simponi) 157

6.2.6 Anti-integrins (Entyvio) 174

6.2.7 Biosimilars 180

7 Unmet Needs Assessment and Opportunity Analysis 185

7.1 Overview 185

7.2 Inadequacy of current anti-TNF- ? drug treatment 186

7.2.1 Unmet need 186

7.2.2 Gap Analysis 187

7.2.3 Opportunity 188

7.3 Patient Adherence 188

7.3.1 Unmet Need 188

7.3.2 Gap Analysis 189

7.3.3 Opportunity 189

7.4 Lack of safe, efficacious and less costly treatment alternatives 190

7.4.1 Unmet Need 190

7.4.2 Gap Analysis 191

7.4.3 Opportunity 192

7.5 Need for novel oral therapies 192

7.5.1 Unmet Need 192

7.5.2 Gap Analysis 192

7.5.3 Opportunity 193

7.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 193

7.6.1 Unmet Need 193

7.6.2 Gap Analysis 194

7.6.3 Opportunity 194

8 Pipeline Assessment 195

8.1 Overview 195

8.2 Promising Drugs in Clinical Development 196

8.2.1 Ustekinumab (Stelara, Suterara, CNTO-1275) 197

8.2.2 Etrolizumab 202

8.2.3 LT-02 (phosphatidylcholine) 207

8.2.4 Kappaproct 213

8.2.5 Xeljanz (Tofacitinib, Cp-690,550) 219

8.2.6 Ozanimod hydrochloride 226

8.2.7 Carotegrast (AJM300) 230

8.2.8 Mesalamine (TP-05) 235

8.2.9 AJG511 238

8.3 Biosimilars 242

8.3.1 Overview 242

8.3.2 Infliximab biosimilars 244

8.3.3 Adalimumab biosimilars 247

8.3.4 Forecast 251

9 Current and Future Players 252

9.1 Overview 252

9.2 Trends in Corporate Strategy 253

9.3 Company Profiles 254

9.3.1 Johnson & Johnson (J&J) 254

9.3.2 AbbVie 256

9.3.3 Takeda Pharmaceuticals 257

9.3.4 Salix Pharmaceuticals 258

9.3.5 Pfizer Inc. 259

9.3.6 F. Hoffmann-La Roche Ltd. 261

9.3.7 InDex Pharmaceuticals 262

9.3.8 Lipid Therapeutics GmbH 263

9.3.9 Celgene Corporation 264

9.3.10 EA Pharma 265

9.3.11 Ferring International 266

9.3.12 Tillotts Pharma 268

10 Market Outlook 270

10.1 Global Markets 270

10.1.1 Forecast 270

10.1.2 Drivers and Barriers-Global Issues 273

10.2 US 276

10.2.1 Forecast 276

10.2.2 Key Events 277

10.2.3 Drivers and Barriers 278

10.3 France 279

10.3.1 Forecast 279

10.3.2 Key Events 282

10.3.3 Drivers and Barriers 282

10.4 Germany 283

10.4.1 Forecast 283

10.4.2 Key Events 286

10.4.3 Drivers and Barriers 286

10.5 Italy 288

10.5.1 Forecast 288

10.5.2 Key Events 290

10.5.3 Drivers and Barriers 290

10.6 Spain 291

10.6.1 Forecast 291

10.6.2 Key Events 294

10.6.3 Drivers and Barriers 294

10.7 United Kingdom 295

10.7.1 Forecast 295

10.7.2 Key Events 298

10.7.3 Drivers and Barriers 298

10.8 Japan 299

10.8.1 Forecast 299

10.8.2 Key Events 302

10.8.3 Drivers and Barriers 302

11 Appendix 305

11.1 Bibliography 305

11.2 Abbreviations 322

11.3 Methodology 327

11.4 Forecasting Methodology 327

11.4.1 Diagnosed Prevalent Patients 327

11.4.2 Percent Drug-Treated Patients 328

11.4.3 Drugs Included in Each Therapeutic Class 328

11.4.4 Launch and Patent Expiry Dates 329

11.4.5 General Pricing Assumptions 329

11.4.6 Individual Drug Assumptions 330

11.4.7 Generic Erosion 335

11.4.8 Pricing of Pipeline Agents 336

11.5 Primary Research-KOLs Interviewed for this Report 337

11.6 Primary Research-Prescriber Survey 339

11.7 About the Authors 340

11.7.1 Analyst 340

11.7.2 Analyst 340

11.7.3 Reviewer 340

11.7.4 Therapy Area Director 341

11.7.5 Epidemiologist 341

11.7.6 Managing Epidemiologist 342

11.7.7 Global Director of Therapy Analysis and Epidemiology 343

11.8 About GlobalData 344

11.9 Disclaimer 344

1.2 List of Figures

Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 32

Figure 2: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025 78

Figure 3: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, 2015 80

Figure 4: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2015 82

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2015 83

Figure 6: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2015 84

Figure 7: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2015 85

Figure 8: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025 86

Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2015 89

Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2015 91

Figure 11:7MM, Age-Standardized Diagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015 92

Figure 12: 7MM, Diagnosed Prevalent Cases of UC Segmented by Severity, Both Cases, All Ages, N, 2015 93

Figure 13: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015 94

Figure 14: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015 95

Figure 15: 7MM. Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015 96

Figure 16: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025 98

Figure 17: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N, 2015 100

Figure 18: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N, 2015 102

Figure 19: 7MM, Age-Standardized Undiagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015 103

Figure 20: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025 104

Figure 21: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N, 2015 106

Figure 22: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N, 2015 108

Figure 23: 7MM, Age-Standardized Total Prevalence of UC, All Ages, Both Sexes, %, 2015 109

Figure 24: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025 110

Figure 25: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025 112

Figure 26 : Ulcerative Colitis Treatment Algorithm 129

Figure 27: Global Sales for Ulcerative Colitis by Drug Class, 2015 and 2025 272

Figure 28: Sales for Ulcerative Colitis by Drug Class in the US, 2015 and 2025 277

Figure 29: Sales for Ulcerative Colitis by Drug Class in France, 2015 and 2025 281

Figure 30: Sales for Ulcerative Colitis by Drug Class in Germany, 2015 and 2025 285

Figure 31: Sales for Ulcerative Colitis by Drug Class in Italy, 2015 and 2025 289

Figure 32: Sales for Ulcerative Colitis by Drug Class in Spain, 2015 and 2025 293

Figure 33: Sales for Ulcerative Colitis by Drug Class in the UK, 2015 and 2025 297

Figure 34: Sales for Ulcerative Colitis by Drug Class in Japan, 2015 and 2025 301

1.1 List of Tables

Table 1: Genetic factors implicated in UC causation 31

Table 2: Truelove and Witts categorization of disease severity and clinical parameters 34

Table 3: Pediatric Ulcerative Colitis Activity Index 35

Table 4: Typical Symptoms of UC 36

Table 5: Risk Factors and Comorbidities for UC and IBD 39

Table 6: Incidence of UC in the 5EU 43

Table 7: Prevalence of UC in Italy, Spain, and the UK 46

Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC 48

Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of UC 49

Table 10: 7MM, Sources Used to Forecast Undiagnosed Prevalent Cases of UC 50

Table 11: 7MM, Sources Used to Forecast the Total Prevalent Cases of UC 51

Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC by Stage at Diagnosis 52

Table 13: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident/Prevalent Cases of UC by Severity 53

Table 14: 7MM, Sources of Epidemiological Data used to Forecast Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC 54

Table 15: 7MM, Sources Used to Forecast Autoimmune Comorbidities Among the Diagnosed Prevalent Cases of UC 55

Table 16: 7MM, Sources Used to Forecast UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management 56

Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IC 57

Table 18: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IC 58

Table 19: 7MM, Sources Not Used in Epidemiological Analysis of UC 76

Table 20: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, Selected Years 2015-2025 77

Table 21: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N (Row %), 2015 79

Table 22: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N (Row %), 2015 81

Table 23: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025 86

Table 24: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015 88

Table 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015 90

Table 26: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Select Years, 2015-2025 97

Table 27: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015 99

Table 28: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015 101

Table 29: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025 104

Table 30: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N (Row %), 2015 105

Table 31: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N (Row %), 2015 107

Table 32: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025 110

Table 33: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025 111

Table 34: Diagnostic features of UC 117

Table 35: Truelove and Witts categorization of disease severity and clinical parameters 118

Table 36: UCDAI 119

Table 37: Pediatric Ulcerative Colitis Activity Index 120

Table 38: Treatment Guidelines for Ulcerative Colitis 121

Table 39: Most Prescribed Drugs for Ulcerative Colitis by Class in the Global Markets, 2015 122

Table 40: Different 5-ASAs used for managing UC 125

Table 41: Different corticosteroids used for managing UC 126

Table 42: Country Profile-US 130

Table 43: Region Profile-5EU 132

Table 44: Country Profile-Japan 136

Table 45: Leading Treatments for UC, 2015 139

Table 46: Product Profile-Lialda 142

Table 47: Efficacy of different drugs in 5-ASA class in inducing remission in UC patients 143

Table 48: Efficacy of different drugs in 5-ASA class in preventing disease relapse in UC patients 143

Table 49: Percentage of patients experiencing adverse events with 5-ASAs 144

Table 50: 5-ASA SWOT Analysis, 2015 144

Table 51: Product Profile -Steroids 147

Table 52: Efficacy of Uceris 148

Table 53: Safety of Uceris 149

Table 54: Uceris SWOT Analysis, 2016 149

Table 55: Product Profile -Azathioprine 151

Table 56: Percentage of patients experiencing adverse events with AZA and 6-MP therapy 153

Table 57: Azathioprine SWOT Analysis, 2015 153

Table 58: Product Profile -MTX 155

Table 59: MTX SWOT Analysis, 2015 157

Table 60: Product Profile -Remicade 160

Table 61: Efficacy data for ACT 1 and ACT 2 trials 161

Table 62: Safety of Remicade 163

Table 63: SWOT Analysis, Remicade 2016 164

Table 64: Product Profile -Humira 166

Table 65: Efficacy of Humira-Primary and Secondary Endpoints-ULTRA 2 Phase III Program 167

Table 66: SWOT Analysis, Humira 2016 168

Table 67: Product Profile -Simponi 170

Table 68: Efficacy of Simponi 171

Table 69: Safety of Simponi 172

Table 70: Simponi SWOT Analysis, 2016 173

Table 71: Product Profile-Entyvio 176

Table 72: Efficacy of Entyvio 177

Table 73: Efficacy of Entyvio 177

Table 74: Safety of Entyvio 178

Table 75: Entyvio SWOT Analysis 179

Table 76: Infliximab Biosimilars for UC Treatment 181

Table 77: Product Profile -Infliximab biosimilar 181

Table 78: Percentage of patients experiencing adverse events with infliximab biosimilars 183

Table 79: Biosimilars SWOT Analysis, 2015 184

Table 80: Unmet Need and Opportunity in UC, 2015 185

Table 81: Late stage development drugs for UC, 2015-2025 196

Table 82: Product Profile-Ustekinumab 198

Table 83: Ustekinumab SWOT Analysis, 2015 201

Table 84: Product Profile-Etrolizumab 203

Table 85: Efficacy of Etrolizumab 204

Table 86:Safety of Etrolizumab 205

Table 87 : Pipeline Drug Etrolizumab SWOT Analysis, 2016 206

Table 88: Product Profile-LT-02 209

Table 89: Efficacy Analysis for LT-02 210

Table 90: Efficacy Analysis for Different Doses of LT-02 211

Table 91: LT-02 SWOT Analysis, 2015 212

Table 92: Product Profile-Kappaproct 215

Table 93: Safety of Kappaproct 217

Table 94: Kappaproct SWOT Analysis, 2016 218

Table 95: Product Profile-Xeljanz 221

Table 96: Patient reported outcomes for Xeljanz compared to placebo 222

Table 97: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups 222

Table 98: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups 223

Table 99: Rates of various adverse events experienced in Xeljanz and placebo groups 223

Table 100: Xeljanz SWOT Analysis, 2015 225

Table 101: Product Profile-Ozanimod hydrochloride 227

Table 102: Efficacy analysis of Ozanimod 228

Table 103: Safety of Ozanimod 228

Table 104: Pipeline Drug Ozanimod SWOT Analysis, 2015 230

Table 105: Product Profile-Carotegrast 232

Table 106: Efficacy analysis in carotegrast and placebo groups 232

Table 107: Safety analysis of carotegrast 233

Table 108: Carotegrast SWOT Analysis, 2015 234

Table 109: Product Profile-Mesalamine (TP-05) 236

Table 110: Pipeline Drug TP-05 SWOT Analysis, 2016 238

Table 111: Product Profile-AJG511 239

Table 112: Efficacy analysis of AJG511 240

Table 113: Carotegrast SWOT Analysis, 2015 242

Table 114: Product Profile-Infliximab biosimilars 245

Table 115: Infliximab biosimilars SWOT Analysis, 2015 247

Table 116: Product Profile-Amjevita 249

Table 117: Amjevita SWOT Analysis, 2016 251

Table 118: Key Companies in the Ulcerative Colitis Market in the 7MM, 2015 252

Table 119: J&J's UC Portfolio Assessment, 2015 255

Table 120: AbbVie's UC Portfolio Assessment, 2015 257

Table 121: Takeda's UC Portfolio Assessment, 2015 258

Table 122: Salix Pharmaceuticals' UC Portfolio Assessment, 2015 259

Table 123: Pfizer's UC Portfolio Assessment, 2015 261

Table 124: Roches UC Portfolio Assessment, 2015 262

Table 125: InDex Pharmaceutical's UC Portfolio Assessment, 2015 263

Table 126: Lipid Therapeutics' UC Portfolio Assessment, 2015 264

Table 127: Celgene's UC Portfolio Assessment, 2015 265

Table 128: EA Pharma's UC Portfolio Assessment, 2015 266

Table 129: Ferring Pharmaceuticals' UC Portfolio Assessment, 2015 268

Table 130: Tillotts Pharma's UC Portfolio Assessment, 2015 269

Table 131:Ulcerative Colitis Market-Global Drivers and Barriers, 2015?2025 273

Table 132: Key Events Impacting Sales for Ulcerative Colitis in the US, 2015-2025 278

Table 133: Ulcerative Colitis Market-Drivers and Barriers in the US, 2015?2025 278

Table 134: Key Events Impacting Sales for Ulcerative Colitis in France, 2015-2025 282

Table 135: Ulcerative Colitis Market-Drivers and Barriers in France, 2015?2025 282

Table 136: Key Events Impacting Sales for Ulcerative Colitis in Germany, 2015-2025 286

Table 137: Ulcerative Colitis Market-Drivers and Barriers in Germany, 2015?2025 286

Table 138: Key Events Impacting Sales for Ulcerative Colitis in Italy, 2015-2025 290

Table 139: Ulcerative Colitis Market-Drivers and Barriers in Italy, 2015?2025 290

Table 140: Key Events Impacting Sales for Ulcerative Colitis in Spain, 2015-2025 294

Table 141: Ulcerative Colitis Market-Drivers and Barriers in Spain, 2015?2025 294

Table 142: Key Events Impacting Sales for Ulcerative Colitis in the UK, 2015-2025 298

Table 143: Ulcerative Colitis Market-Drivers and Barriers in UK, 2015?2025 298

Table 144: Key Events Impacting Sales for Ulcerative Colitis in Japan, 2015-2025 302

Table 145: Ulcerative Colitis Market-Drivers and Barriers in Japan, 2015?2025 302

Table 146: Key Projected Launch Dates for UC 329

Table 147: Key Historical and Projected Patent Expiry Dates for UC 329

Table 148: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 339

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Johnson & Johnson (J&J), AbbVie, Takeda Pharmaceuticals, Salix Pharmaceuticals, Pfizer Inc., F. Hoffmann-La Roche Ltd., InDex Pharmaceuticals, Lipid Therapeutics GmbH, Celgene Corporation, EA Pharma, Ferring International, Tillotts Pharma

select a license

Single User License
USD 10995 INR 710057
Site License
USD 21990 INR 1420114
Corporate User License
USD 32985 INR 2130171

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com